Claims
- 1. A compound of the formula (I):
- 2. The compound of claim 1, wherein the polymer is a biopolymer.
- 3. The compound of claim 1, wherein R1 is substituted with at least one nitric oxide-releasing functional group.
- 4. The compound of claim 1, wherein R1 is unsubstituted or a substituted aryl group.
- 5. The compound of claim 1, wherein R3 is hydrogen.
- 6. The compound of claim 1, wherein each of R1, R2, and R3 is optionally substituted each with 1 to 3 substituents independently selected from the group consisting of alkyl, aryl, alkoxy, aryloxy, acyloxy, benzyl, benzyloxy, acetyl, carboxyl, carboxyalkyl, carboxyalkylamido, carboxydialkylamido, carboxamido, alkylcarbonyl, arylamino, diarylamino, nitrile, tolyl, xylyl, mesityl, anisyl, pyrrolidinyl, formyl, dioxane, alkylthiol, heteroaryl, such as pyran, pyrrole, furan, thiophene, thiazole, pyrazole, pyridine, or pyrimidine, phenylcarbonyl, benzylcarbonyl, nitrophenyl, trialkylsilyl, nitro, sulfonyl, nitrobenzyl, trialkylammonium, tetrahydrofuranyl, tetrahydropyranyl, piperdinyl, morpholinyl, halo, cyano, hydroxy, thiol, cycloalkyl, amino, alkylamino, and dialkylamino.
- 7. A pharmaceutical composition comprising at least one compound of claim 1 and a pharmaceutically acceptable carrier.
- 8. A compound of the formula (I):
- 9. The compound of claim 8, wherein R1 is substituted with at least one nitric oxide-releasing functional group.
- 10. The compound of claim 8, wherein R1 is unsubstituted or a substituted aryl group.
- 11. The compound of claim 8, wherein R3 is hydrogen.
- 12. The compound of claim 8, wherein each of R1, R2, and R3 is optionally substituted each with 1 to 3 substituents independently selected from the group consisting of alkyl, aryl, alkoxy, aryloxy, acyloxy, benzyl, benzyloxy, acetyl, carboxyl, carboxyalkyl, carboxyalkylamido, carboxydialkylamido, carboxamido, alkylcarbonyl, arylamino, diarylamino, nitrile, tolyl, xylyl, mesityl, anisyl, pyrrolidinyl, formyl, dioxane, alkylthiol, heteroaryl, such as pyran, pyrrole, furan, thiophene, thiazole, pyrazole, pyridine, or pyrimidine, phenylcarbonyl, benzylcarbonyl, nitrophenyl, trialkylsilyl, nitro, sulfonyl, nitrobenzyl, trialkylammonium, tetrahydrofuranyl, tetrahydropyranyl, piperdinyl, morpholinyl, halo, cyano, hydroxy, thiol, cycloalkyl, amino, alkylamino, and dialkylamino.
- 13. A compound of formula (IV):
- 14. The compound of claim 13, wherein R1 is substituted with at least one nitric oxide-releasing functional group.
- 15. The compound of claim 13, wherein R1 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl, aryl, alkoxy, aryloxy, acyloxy, benzyl, benzyloxy, acetyl, carboxyl, carboxyalkyl, carboxyalkylamido, carboxydialkylamido, carboxamido, alkylcarbonyl, arylamino, diarylamino, nitrile, tolyl, xylyl, mesityl, anisyl, pyrrolidinyl, formyl, dioxane, alkylthiol, heteroaryl, such as pyran, pyrrole, furan, thiophene, thiazole, pyrazole, pyridine, or pyrimidine, phenylcarbonyl, benzylcarbonyl, nitrophenyl, trialkylsilyl, nitro, sulfonyl, nitrobenzyl, trialkylammonium, tetrahydrofuranyl, tetrahydropyranyl, piperdinyl, morpholinyl, halo, cyano, hydroxy, thiol, cycloalkyl, amino, alkylamino, and dialkylamino.
- 16. A pharmaceutical composition comprising at least one compound of claim 13 and a pharmaceutically acceptable carrier.
- 17. A method of preparing the compound of claim 13 comprising (a) contacting a nitrile of the formula R1CH2CN with a metal alkoxide and an alcohol; (b) contacting the product of (a) with NO to form a diazeniumdiolated nitrile compound; (c) contacting the diazeniumdiolated nitrile compound with an alkoxide and alcohol; and (d) contacting the product of (c) with hydroxide ion.
- 18. A method for treating a biological disorder in a mammal in which dosage with nitric oxide is beneficial, comprising administering to the mammal the compound of claim 13 in an amount sufficient to release a therapeutically effective amount of nitric oxide.
- 19. A method for treating a biological disorder in a mammal in which dosage with nitric oxide is beneficial, comprising administering to the mammal the composition of claim 16 in an amount sufficient to release a therapeutically effective amount of nitric oxide.
- 20. The method of claim 19, wherein the biological disorder is sickle cell anemia.
- 21. The method of claim 19, wherein the biological disorder is leishmania.
- 22. The method of claim 19, wherein the biological disorder is selected from the group consisting of viral infection, bacterial infection, or fungal infection.
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
[0001] This patent application is a divisional of copending U.S. patent application Ser. No. 09/950,162, filed Sep. 10, 2001.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09950162 |
Sep 2001 |
US |
Child |
10702849 |
Nov 2003 |
US |